Sai Life Sciences, one of India's fastest growing Contract Research, Development and  Manufacturing companies, today announced the opening of a new Manufacturing Facility for High Potency Active Pharmaceutical Ingredients at its cGMP API campus manufacturing facility in Bidar, India. With this new facility, the company expands its expertise in the development and manufacture of highly effective pharmaceutical ingredients and offers its customers an optimized path for the development of new chemical substances.
Krishna Kanumuri , CEO and Managing Director of Sai Life Sciences, stated: “In recent years we have seen an increase in oncology drug projects, which has created a need for highly potent pharmaceutical compounds. To better meet this growing need and take advantage of the latest technological advances in the manufacture of highly potent APIs, we have created this new facility. The addition of the latest generation of highly potent active pharmaceutical ingredients to our facilities expands our capabilities to meet the diverse needs of our customers."

The new HPAPI Zone, occupying more than 1,486 m² on the company's Bidar Manufacturing Campus, has the following characteristics:

• Developed and validated for the processing of highly potent molecules with a concentration of less than μg/m 3
• Integrated warehouse for storing the most important starting materials, intermediate products and finished goods
• Dedicated sampling/dosing area with three independent stream separators for processing commercial scale batches
• Multi-unit reactors equipped with separators and split butterfly valves
• powder processing and packaging area with separators; separate dedicated line for quality control

deactivation device
In early 2022, the company opened its facility for the development of highly potent active pharmaceutical ingredients at its R&D campus in Hyderabad  . With the new production facility for high-potency active pharmaceutical ingredients in Bidar, the company is now able to cover all aspects of the project life cycle: process development , analytical development , particle engineering , warehousing, pilot projects, scale-up, sampling, quality control, powder processing, waste water treatment, packaging, transport and Stability Services .

In recent years, the company has undergone an intense period of transformation as part of its Sai-Nxt initiative, investing more than $120 million in its capabilities and operations, expanding into new geographies, expanding its scientific talent and raising the bar for quality, compliance and performance overall.

About Sai Life Sciences

Sai Life Sciences is a full-service CRO-CDMO working with innovative pharmaceutical and biotech companies worldwide to accelerate small molecule discovery, development and commercialization. The company takes a flexible and creative approach to providing its customers with high-quality, cost-effective solutions that accelerate their time to market. Backed by global investors TPG Capital and HBM Healthcare Investments, the company today works with more than 200 innovative companies around the world and employs more than 2,500 people across its offices in India, the UK and the US . https://www.sailife.com/

Photo: https://mma.prnewswire.com/media/1984518/High_Potency_API.jpg
Logo: https://mma.prnewswire.com/media/1044186/Sai_Life_Sciences_Logo.jpg

 

Source:prnewswire.com

Report Abuse